
## Giandomenico Russo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6089477/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Challenging Cutaneous T-Cell Lymphoma: What Animal Models Tell us So Far. Journal of Investigative Dermatology, 2022, , .	0.3	2
2	Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis. Journal of Investigative Dermatology, 2022, 142, 3009-3019.e9.	0.3	4
3	Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome. Cancers, 2022, 14, 2847.	1.7	1
4	Pleomorphicskin eruptions in a COVIDâ€19 affected patient: Case report and review of the literature. Immunity, Inflammation and Disease, 2021, 9, 617-621.	1.3	2
5	Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-CellÂLymphoma. Journal of Investigative Dermatology, 2020, 140, 1045-1053.e6.	0.3	19
6	Protein kinase Akt2/PKBβ is involved in blastomere proliferation of preimplantation mouse embryos. Journal of Cellular Physiology, 2020, 235, 3393-3401.	2.0	7
7	Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. Frontiers in Immunology, 2020, 11, 579894.	2.2	4
8	Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome. Cell Cycle, 2019, 18, 1292-1294.	1.3	2
9	Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance. Leukemia, 2019, 33, 1231-1242.	3.3	28
10	Sézary Syndrome, recent biomarkers and new drugs. Chinese Clinical Oncology, 2019, 8, 2-2.	0.4	13
11	The ACC melanoma pilot project: "Real-world―evaluation of an NGS platform for molecular characterization of melanoma in Italy Journal of Clinical Oncology, 2019, 37, e14600-e14600.	0.8	0
12	Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome. Cell Death and Disease, 2018, 9, 1178.	2.7	10
13	T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1. PLoS ONE, 2018, 13, e0204775.	1.1	5
14	Abstract 761: The role of PI3 kinase pathway in the the skin of Sezary syndrome. , 2018, , .		0
15	Abstract 474: Alterations of micro-RNAs are associated with melanoma resistance to BRAF inhibitors: Role of miR-126. , 2018, , .		1
16	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. Oncogene, 2017, 36, 6617-6626.	2.6	22
17	TCL1., 2017,, 4465-4469.		0
18	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discovery, 2016, 6, 986-1005.	7.7	79

#	Article	IF	CITATIONS
19	TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia. Cell Death and Disease, 2016, 7, e2071-e2071.	2.7	40
20	Abstract 936: Skin microenvironment enhances proliferation index and activates mTORC 1 signaling in sezary syndrome. , 2016, , .		0
21	lgE reactivity and survival probabilities in Sézary syndrome. Journal of the American Academy of Dermatology, 2015, 72, e177.	0.6	3
22	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	13.5	2,562
23	Single TCR-Vβ2 evaluation discloses the circulating T cell clone in Sezary syndrome: one family fits all!. Archives of Dermatological Research, 2015, 307, 487-493.	1.1	5
24	miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eμ-TCL1 mouse model. Oncotarget, 2015, 6, 19807-19818.	0.8	29
25	Abstract 3974: A preclinical study for miR181b as therapeutic in Eu-TCL1FL-tg mouse model for CLL. , 2015, , .		0
26	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	3.2	52
27	Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia, 2013, 27, 170-182.	3.3	145
28	Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: The yin and yang of HCV-driven lymphoproliferation and autoimmunity. Autoimmunity Reviews, 2013, 12, 430-435.	2.5	30
29	<i>BCR/ABL1</i> -positive acute lymphoblastic leukemia relapsing as <i>BCR/ABL1</i> -negative acute lymphoblastic leukemia. Leukemia and Lymphoma, 2013, 54, 2065-2067.	0.6	1
30	Comprehensive analysis of PTEN status in Sézary syndrome. Blood, 2013, 122, 3511-3520.	0.6	47
31	From single-cell signature to prognostic factors: the case of Sézary syndrome. Expert Review of Clinical Immunology, 2012, 8, 699-701.	1.3	1
32	Specific IgE toward Allergenic Molecules Is a New Prognostic Marker in Patients with Sézary Syndrome. International Archives of Allergy and Immunology, 2012, 157, 159-167.	0.9	15
33	miR-24 triggers epidermal differentiation by controlling actin adhesion and cell migration. Journal of Cell Biology, 2012, 199, 347-363.	2.3	87
34	Clonal B cells of HCVâ€associated mixed cryoglobulinemia patients contain exhausted marginal zoneâ€like and CD21 <sup>low</sup> cells overexpressing Stra13. European Journal of Immunology, 2012, 42, 1468-1476.	1.6	40
35	Abstract 4178: Tcl1 enhances keratinocytes' survival/proliferation by promoting erk and jnk/sap phosphorylation at the expense of p38 and by controlling c-fos expression through miR-29b and miR-181a-1. , 2012, , .		0
36	Gistic Evaluation in Sezary Syndrome. Blood, 2012, 120, 4814-4814.	0.6	0

#	Article	IF	CITATIONS
37	MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome. Cell Death and Disease, 2011, 2, e151-e151.	2.7	119
38	Proteomics <i>plus</i> genomics approaches in primary immunodeficiency: the case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Clinical and Experimental Immunology, 2011, 167, 120-128.	1.1	22
39	TCL1., 2011,, 3625-3629.		Ο
40	Abstract 150: Regulation of TGFB receptor by miR21 in Sezary syndrome. , 2011, , .		0
41	Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells. Blood, 2011, 118, 286-286.	0.6	0
42	Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments. British Journal of Dermatology, 2010, 162, 611-618.	1.4	24
43	The role of 9-O-acetylated ganglioside D3 (CD60) and Â4Â1 (CD49d) expression in predicting the survival of patients with Sezary syndrome. Haematologica, 2010, 95, 1905-1912.	1.7	16
44	Abstract 1736: Skewed usage of TCRVbeta repertoire and predictive role of CD60 and CD49d expression in the survival rate of patients with SézÃry Syndrome. , 2010, , .		0
45	Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays. Cancer Research, 2009, 69, 8438-8446.	0.4	68
46	Quality of life and psychological distress in patients with cutaneous lymphoma. British Journal of Dermatology, 2009, 160, 815-822.	1.4	85
47	The Tcl1 oncogene defines secondary hair germ cells differentiation at catagen–telogen transition and affects stem-cell marker CD34 expression. Oncogene, 2009, 28, 1329-1338.	2.6	7
48	Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. International Journal of Cancer, 2008, 123, 1327-1338.	2.3	79
49	TCL1 promotes blastomere proliferation through nuclear transfer, but not direct phosphorylation, of AKT/PKB in early mouse embryos. Cell Death and Differentiation, 2008, 15, 420-422.	5.0	22
50	CXCL13 Is Highly Produced by Selzary Cells and Enhances Their Migratory Ability via a Synergistic Mechanism Involving CCL19 and CCL21 Chemokines. Cancer Research, 2008, 68, 7137-7146.	0.4	45
51	Compatible solutes from hyperthermophiles improve the quality of DNA microarrays. BMC Biotechnology, 2007, 7, 82.	1.7	14
52	Skin homing of Seleary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood, 2006, 107, 1108-1115.	0.6	148
53	Expression of TCL1 and CD27 in primary cutaneous B-cell lymphomas. Histopathology, 2006, 49, 343-348.	1.6	3
54	The B-Cell Chemoattractant Factor CXCL13 Is Expressed in the Malignant Lymphocyte of the Sezary Syndrome Blood, 2006, 108, 2292-2292.	0.6	0

#	Article	IF	CITATIONS
55	Genomic Tumour Profiling with High-Density Oligonucleotide SNP Array in Selzary Syndrome Blood, 2006, 108, 2289-2289.	0.6	0
56	Impaired T- and B-cell development in Tcl1-deficient mice. Blood, 2005, 105, 1288-1294.	0.6	33
57	Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. British Journal of Dermatology, 2005, 153, 324-330.	1.4	44
58	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene, 2005, 24, 4540-4548.	2.6	111
59	a4b1+and a4b7+CD4+T cell numbers increase and CLA+CD4+T cell numbers decrease in systemic sclerosis. Clinical and Experimental Immunology, 2005, 139, 551-557.	1.1	8
60	Familial Cancer Associated with a Polymorphism inARLTS1. New England Journal of Medicine, 2005, 352, 1667-1676.	13.9	119
61	Hepatitis C Virus Drives the Unconstrained Monoclonal Expansion of VH1–69-Expressing Memory B Cells in Type II Cryoglobulinemia: A Model of Infection-Driven Lymphomagenesis. Journal of Immunology, 2005, 174, 6532-6539.	0.4	97
62	Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clinical and Experimental Immunology, 2004, 138, 540-546.	1.1	214
63	Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge) Tj ETQq1	1 0.7843	14 rgBT /Ove
64	Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1. British Journal of Cancer, 2003, 89, 1091-1095.	2.9	5
65	Persistently Biased T-Cell Receptor Repertoires in HIV-1-Infected Combination Antiretroviral Therapy???Treated Patients Despite Sustained Suppression of Viral Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 140-154.	0.9	21
66	TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11712-11717.	3.3	82
67	Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood, 2002, 100, 4082-4089.	0.6	82
68	Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6955-6960.	3.3	557
69	T Cell Receptor-Vβ Analysis Identifies a Dominant CD60+ CD26– CD49d– T Cell Clone in the Peripheral Blood of S©zary Syndrome Patients. Journal of Investigative Dermatology, 2002, 119, 193-196.	0.3	22
70	Acquired Chromosome 11q Deletion Involving the Ataxia Teleangiectasia Locus in B-Cell Non-Hodgkin's Lymphoma: Correlation With Clinicobiologic Features. Journal of Clinical Oncology, 2000, 18, 2607-2614.	0.8	41
71	Low frequency of alterations of the $\hat{t}$ (PPP2R1A) and $\hat{t}^2$ (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene, 2000, 19, 1191-1195.	2.6	206
72	Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia. Oncogene, 2000, 19, 2796-2802.	2.6	45

#	Article	IF	CITATIONS
73	Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3028-33.	3.3	168
74	Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2949-2951.	3.3	109
75	Skewed Expression of Activation, Differentiation and Homing-Related Antigens in Circulating Cells from Patients with Cutaneous T Cell Lymphoma Associated with CD7– T Helper Lymphocytes Expansion. Journal of Investigative Dermatology, 1999, 113, 622-627.	0.3	47
76	Molecular Cloning and Characterization ofZNF202:A New Gene at 11q23.3 Encoding Testis-Specific Zinc Finger Proteins. Genomics, 1998, 52, 358-362.	1.3	34
77	Deregulated expression of TCL1 causes T cell leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 3885-3889.	3.3	146
78	The murine Tcl1 oncogene: embryonic and lymphoid cell expression. Oncogene, 1997, 15, 919-926.	2.6	32
79	The design of a specific ligand of HIV gp120. , 1997, 3, 383-390.		3
80	Exon-Scanning Mutation Analysis of the ATM Gene in Patients with Ataxia-T elangiectasia. European Journal of Human Genetics, 1996, 4, 352-355.	1.4	27
81	The molecular genetics of chromosomal translocations in lymphoid malignancy. Advances in Genome Biology, 1995, 3, 211-231.	0.3	0
82	Identification of the TCL1 gene involved in T-cell malignancies Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 12530-12534.	3.3	257
83	Chromosome walking on the TCL1 locus involved in T-cell neoplasia Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9275-9279.	3.3	74
84	Isolation of a cDNA clone encoding a novel form of granzyme B from human NK cells and mapping to chromosome 14. Human Genetics, 1990, 84, 465-70.	1.8	15
85	Human TCR-gamma+/delta+, CD8+ T lymphocytes recognize tetanus toxoid in an MHC-restricted fashion Journal of Experimental Medicine, 1989, 169, 1847-1851.	4.2	167
86	Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia telangiectasia patient Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 602-606.	3.3	98
87	Molecular resemblance of an AIDS-associated lymphoma and endemic Burkitt lymphomas: implications for their pathogenesis Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8907-8911.	3.3	53
88	Molecular Genetics of Lymphoid Tumorigenesis. Progress in Molecular Biology and Translational Science, 1989, 36, 269-280.	1.9	12
89	Molecular analysis of a t(7;14)(g35;g32) chromosome translocation in a T cell leukemia of a patient with ataxia telangiectasia. Cell, 1988, 53, 137-144.	13.5	117
90	Cloning of the gene encoding the delta subunit of the human T-cell receptor reveals its physical organization within the alpha-subunit locus and its involvement in chromosome translocations in T-cell malignancy Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3933-3937.	3.3	97

#	Article	IF	CITATIONS
91	Hypogammaglobulinemia with hyper-IgM, severe T-cell defect, and abnormal recirculation of OKT4 lymphocytes in a girl with chronic lymphadenopathy. Clinical Immunology and Immunopathology, 1986, 38, 256-264.	2.1	13
92	Phenotypically immature IgG-bearing B cells in patients with hypogammaglobulinemia. Journal of Clinical Immunology, 1986, 6, 21-25.	2.0	19
93	Variant of ataxia-telangiectasia with low-level radiosensitivity. Human Genetics, 1985, 70, 274-7.	1.8	55
94	T-cell receptor genes and ataxia telangiectasia. Nature, 1985, 313, 186-186.	13.7	32
95	Activity of azelaic acid on cultures of lymphoma- and leukemia-derived cell lines, normal resting and stimulated lymphocytes and 3T3 fibroblasts. Biochemical Pharmacology, 1985, 34, 1653-1658.	2.0	29
96	Heterogeneity of immunological abnormalities in ataxia-telangiectasia. Journal of Clinical Immunology, 1983, 3, 135-141.	2.0	58